Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 11/2015

01-11-2015 | Pathogenesis of Hypertension (W Elliott, Section Editor)

Clinical Significance of Endothelial Dysfunction in Essential Hypertension

Authors: Eugenia Gkaliagkousi, Eleni Gavriilaki, Areti Triantafyllou, Stella Douma

Published in: Current Hypertension Reports | Issue 11/2015

Login to get access

Abstract

The endothelium is recognized as a major determinant of vascular physiology and pathophysiology. Over the last few decades, a plethora of studies have implicated endothelial dysfunction in the progression of atherosclerosis and the subclinical target organ damage observed in essential hypertension. However, the clinical significance of diagnosing endothelial dysfunction in patients with essential hypertension remains under investigation. Although a number of vascular and non-vascular markers of endothelial dysfunction have been proposed, there is an ongoing quest for a marker in the clinical setting that is optimal, inexpensive, and reproducible. In addition, endothelial dysfunction emerges as a promising therapeutic target of agents that are readily available in clinical practice. In this context, a better understanding of its role in essential hypertension becomes of great importance. Here, we aim to investigate the clinical significance of endothelial dysfunction in essential hypertension by accumulating novel data on (a) early diagnosis using robust markers with prognostic value in cardiovascular risk prediction, (b) the association of endothelial dysfunction with subclinical vascular organ damage, and (c) potential therapeutic targets.
Literature
1.
Fishman AP. Endothelium: a distributed organ of diverse capabilities. Ann N Y Acad Sci. 1982;401:1–8.CrossRefPubMed
2.
Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315(17):1046–51.CrossRefPubMed
3.••
Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340(8828):1111–5. A innovative study where Celermajer et al described the first non-invasive methodology of endothelial function assessment.CrossRefPubMed
4.
Dharmashankar K, Widlansky ME. Vascular endothelial function and hypertension: insights and directions. Curr Hypertension Rep. 2010;12(6):448–55.CrossRef
5.
Gkaliagkousi E, Ritter J, Ferro A. Platelet-derived nitric oxide signaling and regulation. Circ Res. 2007;101(7):654–62.CrossRefPubMed
6.
Palmer RM, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun. 1988;153(3):1251–6.CrossRefPubMed
7.
Piazza M, Futrega K, Spratt DE, Dieckmann T, Guillemette JG. Structure and dynamics of calmodulin (CaM) bound to nitric oxide synthase peptides: effects of a phosphomimetic CaM mutation. Biochemistry. 2012;51(17):3651–61.CrossRefPubMed
8.
Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res. 2001;88(11):E68–75.CrossRefPubMed
9.
Fleming I, Bauersachs J, Busse R. Calcium-dependent and calcium-independent activation of the endothelial NO synthase. J Vasc Res. 1997;34(3):165–74.CrossRefPubMed
10.
Gkaliagkousi E, Douma S, Zamboulis C, Ferro A. Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertension. J Hypertens. 2009;27(12):2310–20.CrossRefPubMed
11.
12.
List BM, Klosch B, Volker C, Gorren AC, Sessa WC, Werner ER, et al. Characterization of bovine endothelial nitric oxide synthase as a homodimer with down-regulated uncoupled NADPH oxidase activity: tetrahydrobiopterin binding kinetics and role of haem in dimerization. Biochem J. 1997;323(Pt 1):159–65.PubMedCentralCrossRefPubMed
13.
Bevers LM, Braam B, Post JA, van Zonneveld AJ, Rabelink TJ, Koomans HA, et al. Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. Hypertension. 2006;47(1):87–94.CrossRefPubMed
14.
Gkaliagkousi E, Passacquale G, Douma S, Zamboulis C, Ferro A. Platelet activation in essential hypertension: implications for antiplatelet treatment. Am J Hypertens. 2010;23(3):229–36.CrossRefPubMed
15.•
Gkaliagkousi E, Corrigall V, Becker S, de Winter P, Shah A, Zamboulis C, et al. Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension. Eur Heart J. 2009;30(24):3048–54. An original study linking decreased NO bioavailability with platelet activation in essential hypertension.CrossRefPubMed
16.
Gkaliagkousi E, Gavriilaki E, Yiannaki E, Markala D, Papadopoulos N, Triantafyllou A, et al. Platelet activation in essential hypertension during exercise: pre- and post-treatment changes with an angiotensin II receptor blocker. Am J Hypertens. 2014;27(4):571–8.CrossRefPubMed
17.••
Lekakis J, Abraham P, Balbarini A, Blann A, Boulanger CM, Cockcroft J, et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Working Groups Epidemiol Prev Cardiac Rehabil Exerc Physiol. 2011;18(6):775–89. A position statement summarising current markers of endothelial dysfunction.
18.
Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Anal Technol Biomed Life Sci. 2007;851(1-2):42–50.CrossRef
19.
Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005;46(3):518–23.CrossRefPubMed
20.
Juonala M, Viikari JS, Alfthan G, Marniemi J, Kahonen M, Taittonen L, et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation. 2007;116(12):1367–73.CrossRefPubMed
21.
Boger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res Off J Italian Pharmacol Soc. 2009;60(6):481–7.CrossRef
22.•
Boger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009;119(12):1592–600. A large community-based study correlating ADMA with cardiovascular morbidity and mortality.PubMedCentralCrossRefPubMed
23.
Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol. 2011;31(1):27–33.CrossRefPubMed
24.
Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension. 2006;48(2):180–6.CrossRefPubMed
25.
Amabile N, Cheng S, Renard JM, Larson MG, Ghorbani A, McCabe E, et al. Association of circulating endothelial microparticles with cardiometabolic risk factors in the Framingham Heart Study. Eur Heart J. 2014;35(42):2972–9.CrossRefPubMed
26.
Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, et al. The assessment of endothelial function: from research into clinical practice. Circulation. 2012;126(6):753–67.PubMedCentralCrossRefPubMed
27.
Muiesan ML, Salvetti M, Monteduro C, Corbellini C, Guelfi D, Rizzoni D, et al. Flow-mediated dilatation of the brachial artery and left ventricular geometry in hypertensive patients. J Hypertens. 2001;19(3 Pt 2):641–7.CrossRefPubMed
28.
Clarkson P, Celermajer DS, Donald AE, Sampson M, Sorensen KE, Adams M, et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol. 1996;28(3):573–9.CrossRefPubMed
29.
Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993;88(5 Pt 1):2149–55.CrossRefPubMed
30.
Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24(6):1468–74.CrossRefPubMed
31.
Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26(5):1235–41.CrossRefPubMed
32.
Halcox JP, Donald AE, Ellins E, Witte DR, Shipley MJ, Brunner EJ, et al. Endothelial function predicts progression of carotid intima-media thickness. Circulation. 2009;119(7):1005–12.CrossRefPubMed
33.
Yeboah J, Crouse JR, Bluemke DA, Lima JA, Polak JF, Burke GL, et al. Endothelial dysfunction is associated with left ventricular mass (assessed using MRI) in an adult population (MESA). J Hum Hypertens. 2011;25(1):25–31.PubMedCentralCrossRefPubMed
34.
Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation. 2007;115(18):2390–7.CrossRefPubMed
35.
Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009;120(6):502–9.PubMedCentralCrossRefPubMed
36.
Huang AL, Silver AE, Shvenke E, Schopfer DW, Jahangir E, Titas MA, et al. Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. Arterioscler Thromb Vasc Biol. 2007;27(10):2113–9.PubMedCentralCrossRefPubMed
37.
Hafner F, Kieninger A, Meinitzer A, Gary T, Froehlich H, Haas E, et al. Endothelial dysfunction and brachial intima-media thickness: long term cardiovascular risk with claudication related to peripheral arterial disease: a prospective analysis. PLoS One. 2014;9(4):e93357.PubMedCentralCrossRefPubMed
38.
Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002;40(3):505–10.CrossRefPubMed
39.
Takishima I, Nakamura T, Hirano M, Kitta Y, Kobayashi T, Fujioka D, et al. Predictive value of serial assessment of endothelial function in chronic heart failure. Int J Cardiol. 2012;158(3):417–22.CrossRefPubMed
40.•
Yang Y, Xu JZ, Wang Y, Tang XF, Gao PJ. Brachial flow-mediated dilation predicts subclinical target organ damage progression in essential hypertensive patients: a 3-year follow-up study. J Hypertens. 2014;32(12):2393–400. discussion 2400. A prospective study implicating FMD as an early marker of subclinical target organ damage in patients with essential hypertension.CrossRefPubMed
41.
Laurent S, Briet M, Boutouyrie P. Large and small artery cross-talk and recent morbidity-mortality trials in hypertension. Hypertension. 2009;54(2):388–92.CrossRefPubMed
42.
Ott C, Raff U, Harazny JM, Michelson G, Schmieder RE. Central pulse pressure is an independent determinant of vascular remodeling in the retinal circulation. Hypertension. 2013;61(6):1340–5.CrossRefPubMed
43.
Triantafyllou A, Anyfanti P, Gavriilaki E, Zabulis X, Gkaliagkousi E, Petidis K, et al. Association between retinal vessel caliber and arterial stiffness in a population comprised of normotensive to early-stage hypertensive individuals. Am J Hypertens. 2014;27(12):1472–8.CrossRefPubMed
44.
Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation. 2002;105(2):213–7.CrossRefPubMed
45.
Schmitt M, Avolio A, Qasem A, McEniery CM, Butlin M, Wilkinson IB, et al. Basal NO locally modulates human iliac artery function in vivo. Hypertension. 2005;46(1):227–31.CrossRefPubMed
46.
Stewart AD, Millasseau SC, Kearney MT, Ritter JM, Chowienczyk PJ. Effects of inhibition of basal nitric oxide synthesis on carotid-femoral pulse wave velocity and augmentation index in humans. Hypertension. 2003;42(5):915–8.CrossRefPubMed
47.
Nigam A, Mitchell GF, Lambert J, Tardif JC. Relation between conduit vessel stiffness (assessed by tonometry) and endothelial function (assessed by flow-mediated dilatation) in patients with and without coronary heart disease. Am J Cardiol. 2003;92(4):395–9.CrossRefPubMed
48.
Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588–605.CrossRefPubMed
49.
Kobayashi K, Akishita M, Yu W, Hashimoto M, Ohni M, Toba K. Interrelationship between non-invasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intima-media thickness and pulse wave velocity. Atherosclerosis. 2004;173(1):13–8.CrossRefPubMed
50.
Koivistoinen T, Virtanen M, Hutri-Kahonen N, Lehtimaki T, Jula A, Juonala M, et al. Arterial pulse wave velocity in relation to carotid intima-media thickness, brachial flow-mediated dilation and carotid artery distensibility: the Cardiovascular Risk in Young Finns Study and the Health 2000 Survey. Atherosclerosis. 2012;220(2):387–93.CrossRefPubMed
51.
Horvath T, Pinter A, Kollai M. Carotid artery stiffness is not related to endothelial function in young healthy subjects. Autonomic Neurosci Basic Clin. 2012;166(1-2):85–8.CrossRef
52.
Dubin R, Owens C, Gasper W, Ganz P, Johansen K. Associations of endothelial dysfunction and arterial stiffness with intradialytic hypotension and hypertension. Hemodial Int Int Symp Home Hemodial. 2011;15(3):350–8.CrossRef
53.
Cakar M, Bulucu F, Karaman M, Ay SA, Kurt O, Balta S, Demirkol S, Sarlak H, Akhan M, Altun B et al: Asymmetric Dimethylarginine and Augmentation Index in Newly Diagnosed Patients With Hypertension. Angiology 2013
54.
Wang KL, Cheng HM, Chuang SY, Spurgeon HA, Ting CT, Lakatta EG, et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens. 2009;27(3):461–7.PubMedCentralCrossRefPubMed
55.
Gkaliagkousi E, Gavriilaki E, Nikolaidou B, Chatzopoulou F, Anyfanti P, Triantafyllou A, Petidis K, Zamboulis C, Douma S: Association Between Cardiotrophin 1 Levels and Central Blood Pressure in Untreated Patients With Essential Hypertension. American journal of hypertension 2014.
56.
Gkaliagkousi E, Doumas M, Gavriilaki E, Triantafyllou A, Vogiatzis K, Anyfanti P, et al. Elevated levels of MMP-9 in untreated patients with stage I essential hypertension. Clin Exp Hypertens. 2012;34(8):561–6.CrossRefPubMed
57.
Michelson G, Warntges S, Harazny J, Oehmer S, Delles C, Schmieder RE. Effect of nos inhibition on retinal arterial and capillary circulation in early arterial hypertension. Retina. 2006;26(4):437–44.CrossRefPubMed
58.
Hemminki V, Laakso J, Kahonen M, Turjanmaa V, Uusitalo H, Lehtimaki T, et al. Plasma asymmetric dimethylarginine and retinal vessel diameters in middle-aged men. Metab Clin Exp. 2007;56(10):1305–10.CrossRefPubMed
59.
Tsioufis C, Dimitriadis K, Andrikou E, Thomopoulos C, Tsiachris D, Stefanadi E, et al. ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. Am J Kidney Dis Off J National Kidney Found. 2010;55(6):1050–9.CrossRef
60.
Rochette L, Lorin J, Zeller M, Guilland JC, Lorgis L, Cottin Y, et al. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol Ther. 2013;140(3):239–57.CrossRefPubMed
61.•
Shatanawi A, Romero MJ, Iddings JA, Chandra S, Umapathy NS, Verin AD, et al. Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am J Physiol Cell Physiol. 2011;300(5):C1181–1192. A recent review with a detailed description of possible therapeutic targets of endothelial dysfunction in patients at increased cardiovascular risk.PubMedCentralCrossRefPubMed
62.
Endtmann C, Ebrahimian T, Czech T, Arfa O, Laufs U, Fritz M, et al. Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration. Hypertension. 2011;58(3):394–403.CrossRefPubMed
63.
He HL, Liu L, Chen QH, Cai SX, Han JB, Hu SL, et al. MSCs modified with ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS. J Cell Physiol. 2015;230(3):691–701.CrossRefPubMed
64.
Schlimmer N, Kratz M, Bohm M, Baumhakel M. Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis. Br J Pharmacol. 2011;163(4):804–14.PubMedCentralCrossRefPubMed
65.
Yung LM, Wong WT, Tian XY, Leung FP, Yung LH, Chen ZY, et al. Inhibition of renin-angiotensin system reverses endothelial dysfunction and oxidative stress in estrogen deficient rats. PLoS One. 2011;6(3):e17437.PubMedCentralCrossRefPubMed
66.
Nemoto S, Kobayashi T, Taguchi K, Matsumoto T, Kamata K. Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats. Am J Physiol Heart Circ Physiol. 2011;301(6):H2383–2394.CrossRefPubMed
67.
Tian S, Ge X, Wu K, Yang H, Liu Y. Ramipril protects the endothelium from high glucose-induced dysfunction through CaMKKbeta/AMPK and heme oxygenase-1 activation. J Pharmacol Exp Rapeutics. 2014;350(1):5–13.CrossRef
68.
Toba H, Wang J, Ohigashi M, Kobara M, Nakata T. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-gamma activation in hypertensive 5/6 nephrectomized rats. Pharmacology. 2013;92(5-6):265–75.CrossRefPubMed
69.
Marampon F, Gravina GL, Scarsella L, Festuccia C, Lovat F, Ciccarelli C, et al. Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated endothelial cell dysfunction by modulating the p38/SirT1 axis. J Hypertens. 2013;31(10):1972–83.CrossRefPubMed
70.
Siragusa M, Sessa WC. Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival. Arterioscler Thromb Vasc Biol. 2013;33(8):1852–60.CrossRefPubMed
71.
Mak IT, Landgraf KM, Chmielinska JJ, Weglicki WB. Angiotensin II promotes iron accumulation and depresses PGI(2) and NO synthesis in endothelial cells: effects of losartan and propranolol analogs. Can J Physiol Pharmacol. 2012;90(10):1413–8.PubMedCentralCrossRefPubMed
72.
Georgescu A, Alexandru N, Andrei E, Titorencu I, Dragan E, Tarziu C, et al. Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan. J Thromb Haemost JTH. 2012;10(4):680–91.CrossRefPubMed
73.
Toyama T, Sato C, Koyama K, Kasama S, Murakami J, Yamashita E, et al. Olmesartan improves coronary flow reserve of hypertensive patients using coronary magnetic resonance imaging compared with amlodipine. Cardiology. 2012;122(4):230–6.CrossRefPubMed
74.
Cherney DZ, Scholey JW, Jiang S, Har R, Lai V, Sochett EB, et al. The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes. Diabetes Care. 2012;35(11):2324–30.PubMedCentralCrossRefPubMed
75.
Zankl AR, Ivandic B, Andrassy M, Volz HC, Krumsdorf U, Blessing E, et al. Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease. Clin Res cardiol Off J German Cardiac Soc. 2010;99(12):787–94.CrossRef
76.
Terashima M, Kaneda H, Nasu K, Matsuo H, Habara M, Ito T, et al. Protective effect of telmisartan against endothelial dysfunction after coronary drug-eluting stent implantation in hypertensive patients. J Am Coll Cardiol Intv. 2012;5(2):182–90.CrossRef
77.
Suzuki R, Fukuda N, Katakawa M, Tsunemi A, Tahira Y, Matsumoto T, et al. Effects of an angiotensin II receptor blocker on the impaired function of endothelial progenitor cells in patients with essential hypertension. Am J Hypertens. 2014;27(5):695–701.CrossRefPubMed
78.
Cangiano E, Marchesini J, Campo G, Francolini G, Fortini C, Carra G, et al. ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes. Am J cardiovasc Drugs Drugs devices Other interv. 2011;11(3):189–98.CrossRef
79.
Shahin Y, Khan JA, Samuel N, Chetter I. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis. 2011;216(1):7–16.CrossRefPubMed
80.
Mason RP, Jacob RF, Corbalan JJ, Kaliszan R, Malinski T. Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes. Am J Hypertens. 2014;27(3):482–8.PubMedCentralCrossRefPubMed
81.
He X, Zhang HL, Zhao M, Yang JL, Cheng G, Sun L, et al. Amlodipine ameliorates endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2011;38(4):255–61.CrossRefPubMed
82.
Zhou MS, Tian R, Jaimes EA, Raij L. Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension. Am J Hypertens. 2014;27(6):873–80.CrossRefPubMed
83.
Okamura T, Tawa M, Geddawy A, Shimosato T, Iwasaki H, Shintaku H, et al. Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats. J Pharmacol Sci. 2014;124(1):76–85.CrossRefPubMed
84.
He Y, Si D, Yang C, Ni L, Li B, Ding M, et al. The effects of amlodipine and S(-)-amlodipine on vascular endothelial function in patients with hypertension. Am J Hypertens. 2014;27(1):27–31.CrossRefPubMed
85.
Bayar E, Ilhan G, Furat C, Atik C, Arslanoglu Y, Kuran C, et al. The effect of different beta-blockers on vascular graft nitric oxide levels: comparison of nebivolol versus metoprolol. Eur J Vascular Endovascular Surg Off J Eur Soc Vasc Surg. 2014;47(2):204–8.CrossRef
86.
Mason RP, Jacob RF, Corbalan JJ, Szczesny D, Matysiak K, Malinski T. The favorable kinetics and balance of nebivolol-stimulated nitric oxide and peroxynitrite release in human endothelial cells. BMC Pharmacol Toxicol. 2013;14:48.PubMedCentralCrossRefPubMed
87.
Doggen K, Fransen P, Lemmens K, De Keulenaer GW. Effects of nebivolol on vascular endothelial and myocardial function in diabetes mellitus. J Cardiovasc Pharmacol. 2011;58(1):56–64.CrossRefPubMed
88.
Wang Y, Zhang M, Liu Y, Chen M. The effect of nebivolol on asymmetric dimethylarginine system in spontaneously hypertension rats. Vasc Pharmacol. 2011;54(1-2):36–43.CrossRef
89.
Sorrentino SA, Doerries C, Manes C, Speer T, Dessy C, Lobysheva I, et al. Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional beta1-blockade. J Am Coll Cardiol. 2011;57(5):601–11.CrossRefPubMed
90.
Zepeda RJ, Castillo R, Rodrigo R, Prieto JC, Aramburu I, Brugere S, et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic Clin Pharmacol Toxicol. 2012;111(5):309–16.CrossRefPubMed
91.
Khan BV, Rahman ST, Haque T, Merchant N, Bhaheetharan S, Harris 3rd J, et al. Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study. J Cardiovasc Pharmacol Ther. 2012;17(3):291–7.CrossRefPubMed
92.
Sacco G, Evangelista S, Manzini S, Parlani M, Bigioni M. Combined antihypertensive and cardioprotective effects of nebivolol and hydrochlorothiazide in spontaneous hypertensive rats. Futur Cardiol. 2011;7(6):757–63.CrossRef
93.
Pasini AF, Garbin U, Stranieri C, Boccioletti V, Mozzini C, Manfro S, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens. 2008;21(11):1251–7.CrossRefPubMed
94.
Momi S, Caracchini R, Falcinelli E, Evangelista S, Gresele P. Stimulation of platelet nitric oxide production by nebivolol prevents thrombosis. Arterioscler Thromb Vasc Biol. 2014;34(4):820–9.CrossRefPubMed
95.
Vitale C, Marazzi G, Iellamo F, Spoletini I, Dall’Armi V, Fini M, et al. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. Int J Cardiol. 2012;155(2):279–84.CrossRefPubMed
96.
Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003;23(5):729–36.CrossRefPubMed
97.
Reriani MK, Dunlay SM, Gupta B, West CP, Rihal CS, Lerman LO, et al. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovascular Prev Rehabil Off J Eur Soc Cardiol Working Groups Epidemiol Prev Cardiac Rehabil Exerc Physiol. 2011;18(5):704–16.
98.
Wang Q, Yang M, Xu H, Yu J. Tetrahydrobiopterin improves endothelial function in cardiovascular disease: a systematic review. Evid-Based Complement Altern Med eCAM. 2014;2014:850312.
99.
Porkert M, Sher S, Reddy U, Cheema F, Niessner C, Kolm P, et al. Tetrahydrobiopterin: a novel antihypertensive therapy. J Hum Hypertens. 2008;22(6):401–7.CrossRefPubMed
Metadata
Title
Clinical Significance of Endothelial Dysfunction in Essential Hypertension
Authors
Eugenia Gkaliagkousi
Eleni Gavriilaki
Areti Triantafyllou
Stella Douma
Publication date
01-11-2015
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 11/2015
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-015-0596-3

Other articles of this Issue 11/2015

Current Hypertension Reports 11/2015 Go to the issue

Prevention of Hypertension: Public Health Challenges (P Muntner, Section Editor)

Mechanisms Influencing Circadian Blood Pressure Patterns Among Individuals with HIV

Hypertension and the Kidney (RM Carey, Section Editor)

Current Approaches to Quantifying Tonic and Reflex Autonomic Outflows Controlling Cardiovascular Function in Humans and Experimental Animals

Preeclampsia (V Garovic, Section Editor)

Preeclampsia: Syndrome or Disease?

Prevention of Hypertension: Public Health Challenges (P Muntner, Section Editor)

The Utility of Ambulatory Blood Pressure Monitoring for Diagnosing White Coat Hypertension in Older Adults

Hypertension and the Brain (S Stocker, Section Editor)

Exercise for Hypertension: A Prescription Update Integrating Existing Recommendations with Emerging Research
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits